| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911355 | Lung Cancer | 2012 | 6 Pages |
Abstract
Although according to the protocol rules the trial should not be stopped, the lack of any objective response either by CT-scan or PET-CT, along with substantial toxicity, did not argue in favor of the current strategy of B as a single agent in the front-line setting of NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Benjamin Besse, David Planchard, Anne-Sophie Veillard, Laurent Taillade, David Khayat, Muriel Ducourtieux, Jean-Pierre Pignon, Jean Lumbroso, Carole Lafontaine, Claire Mathiot, Jean-Charles Soria,